Treatment of disorders secondary to organic impairments

a technology for organic impairment and disorders, applied in the field of treating disorders secondary to organic impairment, can solve the problems of major psychiatric disturbance, abnormal limbic or neuronal sensitization, hyperactivity, and hypersensitivity, and achieve the effect of reducing attention, hyperactivity, and hyperactivity, and preventing the development of ptsd

a technology for organic impairment and disorders, applied in the field of treating disorders secondary to organic impairment, can solve the problems of major psychiatric disturbance, abnormal limbic or neuronal sensitization, hyperactivity, and hypersensitivity, and achieve the effect of reducing attention, hyperactivity, and hyperactivity, and preventing the development of ptsd

US20030207943A1Inactive Publication Date: 2003-11-06SNOWDEN PHARMA
0 Cites 2 Cited by

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0056] 1. Severe Atypical Psychosis (Problem No.9)

[0057] Sibutramine Patient No.97:

[0058] A 33-year-old male patient had been treated for a severe psychosis which emanated from a motor vehicle accident with head trauma. Symptoms included multiple hallucinations (visual, auditory, smell, and touch), paranoid delusions, confusion, impaired memory, and discontinuity in awareness. He had received various a psychiatric diagnoses and had been treated without success with haloperidol, risperidone, olanzapine, trifluoperazine, buspirone, paroxetine, lorazepam, amantadine, and fluoxetine. SPECT brain scan showed multiple foci of dysfunctions in the right hemisphere indicative of right hemisphere encephalopathy (rather than a primary psychiatric disorder). Treatment with carbamazepine and quetiapine did not control his symptoms and valproic acid was also added. Finally, the patient was started on sibutramine 10 mg orally three times a day and the patient noted a marked decrease in hallucinati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
body mass indexaaaaaaaaaa
weightaaaaaaaaaa
Login to View More

Abstract

A method for treatment of neuropsychiatric symptoms or disorders emanating from primary brain or systemic impairments includes administration of an effective dose of a dopamine, serotonin, and norepinephrine reuptake inhibitor to a human in need of such treatment. The preferred reuptake inhibitor is sibutramine.

Description

[0001] This application is a continuation-in-part application of U.S. application Ser. No. 09 / 204,124 filed Dec. 2, 1998.[0002] The present invention relates to the pharmacological treatment of various secondary neurological, behavioral and cognitive symptoms or disorders emanating out of brain or systemic impairments, i.e, primary impairments.[0003] The secondary symptoms and disorders include as non-limiting examples, tic and behavioral disorders including Tourette's syndrome and severe non-Tourette's motor or vocal tics; Posttraumatic Stress Disorder (PTSD); a typical attention deficit disorder with or without hyperactivity; frontal lobe defects of executive function; oscillopsia; self-mutilation; violence or rage such as in intermittent explosive disorder; asocial behavior; sexual disorders (including gender choice difficulties or hyposexuality); psychological (psychosis, violence, and confusion) and motor symptoms of Huntington's Disease (Huntington's Chorea); fatigue, exhausti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
06 Nov 2003
Publication
US20030207943A1
IPC
A61K31/00; A61K45/00; A61K31/135; A61K31/137; A61P3/00; A61P5/00; A61P15/00; A61P25/00; A61P25/08; A61P25/14; A61P25/18; A61P25/20; A61P25/30; A61P25/36; A61P27/02; A61P31/12
CPC
A61K31/135; A61K31/00; A61P15/00; A61P25/00; A61P25/08; A61P25/14; A61P25/18; A61P25/20
Inventors
MUELLER, PETER STERLING